FR3096459B1 - Procédé de préparation d’un échantillon peptidique - Google Patents

Procédé de préparation d’un échantillon peptidique Download PDF

Info

Publication number
FR3096459B1
FR3096459B1 FR1905247A FR1905247A FR3096459B1 FR 3096459 B1 FR3096459 B1 FR 3096459B1 FR 1905247 A FR1905247 A FR 1905247A FR 1905247 A FR1905247 A FR 1905247A FR 3096459 B1 FR3096459 B1 FR 3096459B1
Authority
FR
France
Prior art keywords
preparing
peptide sample
sample
detecting
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1905247A
Other languages
English (en)
Other versions
FR3096459A1 (fr
Inventor
Sylvain Lehmann
Christophe Hirtz
Jérôme Vialaret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spot To Lab
Universite de Montpellier I
Centre Hospitalier Universitaire de Montpellier CHUM
Universite de Montpellier
Original Assignee
Spot To Lab
Universite de Montpellier I
Centre Hospitalier Universitaire de Montpellier CHUM
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spot To Lab, Universite de Montpellier I, Centre Hospitalier Universitaire de Montpellier CHUM, Universite de Montpellier filed Critical Spot To Lab
Priority to FR1905247A priority Critical patent/FR3096459B1/fr
Priority to US17/595,460 priority patent/US20220196524A1/en
Priority to JP2021569322A priority patent/JP2022533431A/ja
Priority to CA3140439A priority patent/CA3140439A1/fr
Priority to PCT/EP2020/063944 priority patent/WO2020234287A1/fr
Priority to EP20728688.1A priority patent/EP3973296A1/fr
Publication of FR3096459A1 publication Critical patent/FR3096459A1/fr
Application granted granted Critical
Publication of FR3096459B1 publication Critical patent/FR3096459B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4044—Concentrating samples by chemical techniques; Digestion; Chemical decomposition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente demande concerne un procédé de préparation d’un échantillon peptidique à partir d’un échantillon biologique, et un procédé de détection ou de quantification de protéines comprenant ledit procédé de préparation d’un échantillon. L’invention concerne également l’utilisation de ces procédés pour la détection ou le suivi d’une condition ou d’une maladie. Figure à publier avec l’abrégé : Fig. 2
FR1905247A 2019-05-20 2019-05-20 Procédé de préparation d’un échantillon peptidique Active FR3096459B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1905247A FR3096459B1 (fr) 2019-05-20 2019-05-20 Procédé de préparation d’un échantillon peptidique
US17/595,460 US20220196524A1 (en) 2019-05-20 2020-05-19 Process for preparing a peptide sample
JP2021569322A JP2022533431A (ja) 2019-05-20 2020-05-19 ペプチド試料を調製する方法
CA3140439A CA3140439A1 (fr) 2019-05-20 2020-05-19 Procede de preparation d'un echantillon peptidique
PCT/EP2020/063944 WO2020234287A1 (fr) 2019-05-20 2020-05-19 Procédé de préparation d'un échantillon peptidique
EP20728688.1A EP3973296A1 (fr) 2019-05-20 2020-05-19 Procédé de préparation d'un échantillon peptidique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1905247A FR3096459B1 (fr) 2019-05-20 2019-05-20 Procédé de préparation d’un échantillon peptidique
FR1905247 2019-05-20

Publications (2)

Publication Number Publication Date
FR3096459A1 FR3096459A1 (fr) 2020-11-27
FR3096459B1 true FR3096459B1 (fr) 2024-03-08

Family

ID=67957056

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1905247A Active FR3096459B1 (fr) 2019-05-20 2019-05-20 Procédé de préparation d’un échantillon peptidique

Country Status (6)

Country Link
US (1) US20220196524A1 (fr)
EP (1) EP3973296A1 (fr)
JP (1) JP2022533431A (fr)
CA (1) CA3140439A1 (fr)
FR (1) FR3096459B1 (fr)
WO (1) WO2020234287A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118501437A (zh) * 2024-07-18 2024-08-16 西北师范大学 一种用于检测血浆中crp的荧光侧流免疫层析试纸条

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3001805B1 (fr) 2013-02-01 2015-02-20 Biomerieux Sa Procede de detection d'un cancer colorectal
MX2018009339A (es) * 2016-02-04 2019-01-10 Oncobiologics Inc Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas.
US20200355582A1 (en) * 2017-08-01 2020-11-12 Amgen Inc. Systems and Methods for Performing a Real-Time Assay of a Sample

Also Published As

Publication number Publication date
FR3096459A1 (fr) 2020-11-27
CA3140439A1 (fr) 2020-11-26
JP2022533431A (ja) 2022-07-22
WO2020234287A1 (fr) 2020-11-26
EP3973296A1 (fr) 2022-03-30
US20220196524A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
WO2007126758A3 (fr) Procédé et système permettant de déterminer si un médicament sera efficace chez un patient atteint d'une maladie
García et al. Upregulated expression of heparanase and heparanase 2 in the brains of Alzheimer’s disease
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
WO2007016367A3 (fr) Procedes, kits, systemes et bases de donnees relatifs a des maladies neoplasiques
Harding et al. Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion
Villarreal et al. Chronic verubecestat treatment suppresses amyloid accumulation in advanced aged Tg2576-AβPP swe mice without inducing microhemorrhage
FR3096459B1 (fr) Procédé de préparation d’un échantillon peptidique
DK1416965T3 (da) Assayfremgangsmåde til Alzheimers sygdom
FR3044312B1 (fr) Polypeptides mutes de hev et leur utilisation pour le dosage d'anticorps anti-hev
RU2019121662A (ru) Способы использования галектин-3-связывающего белка, обнаруживаемого в моче, для мониторинга тяжести и прогрессирования волчаночного нефрита
CA2574417A1 (fr) Timp-2 en tant que cible/marqueur de defaillance de cellules beta
Persu et al. A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c. 3691+ 1G> A (IVS25+ 1G> A), causes a dramatic increase in circulating ACE through deletion of the transmembrane anchor
ATE415629T1 (de) In-vitro-diagnoseverfahren und kit für eine schwarzschimmel-infektion
Mollee et al. Monitoring of light chain myeloma-time for a change
Basset et al. Proteinuria e albuminuria nelle discrasie plasmacellulari
Hamkour et al. Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response
DK1393078T3 (da) Fremgangsmåder til diagnosticering in vitro eller til overvågning af en sygdom involverende en inflammatorisk reaktion
Staals et al. Haptoglobin phenotype correlates with the extent of cerebral deep white matter lesions in hypertensive patients
Ahmed et al. Prevalence of proteinuria in rural adult population in Tamil Nadu
Qiao et al. Interaction of renin-angiotensin system gene polymorphisms with hypertension in Chinese patients with type 1 diabetes and retinopathy
CN105556306B (zh) 用于监测多发性硬化(ms)的方法和预后试剂盒
FR3094494B1 (fr) Procédé de détection ou de suivi de l’évolution d’une maladie chronique proliférative par dosage immunologique
WO2023235871A3 (fr) Systèmes, compositions et procédés se rapportant à des maladies neurodégénératives
Nilsson et al. The use of N-terminal pro-brain natriuretic Peptide to evaluate vascular disease in elderly patients with mental illness
Chen et al. POS-561 THE TIMING OF DIALYSIS INITIATION AND SURVIVAL OUTCOMES IN YOUNG AND ELDERLY PATIENTS WITH END-STAGE RENAL DISEASE IN MAINLAND CHINA

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20201127

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6